Core Viewpoint - Globavend Holdings Limited has announced a public offering expected to generate approximately $1.4 million in gross proceeds, aimed at enhancing its working capital and general corporate purposes [1][2]. Group 1: Offering Details - The offering consists of 889,359 ordinary shares or pre-funded warrants, with an effective purchase price of $1.60 per share [2]. - The offering is anticipated to close on January 2, 2026, with Univest Securities, LLC serving as the sole placement agent [2]. Group 2: Company Overview - Globavend Holdings Limited is an emerging e-commerce logistics provider, offering end-to-end logistics solutions primarily in Hong Kong, Australia, and New Zealand [4]. - The company serves enterprise customers, including e-commerce merchants and platforms, facilitating business-to-consumer (B2C) transactions [4]. - Globavend provides integrated cross-border logistics services, including parcel drop-off, consolidation, air-freight forwarding, customs clearance, transportation, and final delivery [4].

Core Insights - Voltalia has commenced construction of the Artemisya hybrid cluster in Uzbekistan, which includes 100 megawatts of storage and 100 megawatts of wind capacity, marking a significant advancement in the country's energy storage infrastructure [1][3]. Group 1: Project Details - The Artemisya project consists of a 25-year electricity sales contract for solar and wind generation, alongside a 15-year contract for storage, which includes 126 megawatts of solar, 300 megawatts of wind, and 100 megawatts / 200 megawatt-hours of batteries [2]. - The first phase of Artemisya, which includes 100 megawatts / 200 megawatt-hours of storage and the initial 100-megawatt wind tranche, is set to be completed by 2027 following investment agreements signed on December 5, 2025 [3]. Group 2: Strategic Importance - The Artemisya hybrid cluster, located in the Bukhara region, aims to enhance the flexibility and reliability of Uzbekistan's power system, contributing to the national goal of achieving eight gigawatts of renewable capacity by 2026 and twelve gigawatts by 2030, while also significantly reducing CO₂ emissions [4]. Group 3: Company Commitment - Voltalia's CEO, Robert Klein, emphasized the company's commitment to supporting Uzbekistan's energy transition, highlighting the importance of hybrid solutions, including storage, in ensuring grid stability and optimizing renewable energy integration [5]. Group 4: Company Overview - Voltalia operates with a total capacity of 3.3 gigawatts in operation and under construction, alongside a project portfolio of 17.4 gigawatts under development, positioning itself as a key player in the renewable energy sector [6]. - The company employs over 2,000 staff across 20 countries, enabling it to provide comprehensive services to its clients globally [8].

Primary Mortgage Market Survey® U.S. weekly average mortgage rates as of 12/31/2025 MCLEAN, Va., Dec. 31, 2025 (GLOBE NEWSWIRE) -- Freddie Mac (OTCQB: FMCC) today released the results of its Primary Mortgage Market Survey® (PMMS®), showing the 30-year fixed-rate mortgage (FRM) averaged 6.15%. “After starting the year close to 7%, the average 30-year fixed-rate mortgage moved to its lowest level in 2025 this week, an encouraging sign for potential homebuyers heading into the new year,” said Sam Khater, F ...

Core Insights - Valneva SE and Serum Institute of India have mutually agreed to discontinue their license agreement for Valneva's single-shot chikungunya vaccine, allowing Valneva to regain full rights and control over its supply chain and commercialization efforts in endemic high-risk countries [1][2] Group 1: Company Overview - Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases, addressing unmet medical needs [5] - The company has advanced multiple vaccines from early R&D to approvals and currently markets three proprietary travel vaccines [6] - Valneva's revenue from its growing commercial business supports the advancement of its vaccine pipeline, which includes a Lyme disease vaccine candidate partnered with Pfizer and a Shigella vaccine candidate [7] Group 2: Chikungunya Vaccine Context - Chikungunya virus (CHIKV) is a mosquito-borne disease causing severe joint pain, fever, and other symptoms, with significant economic and medical burdens expected to grow due to climate change [3][4] - Since 2004, chikungunya has spread to over 110 countries, with more than 3.7 million cases reported in the Americas between 2013 and 2023, highlighting the disease as a major public health problem according to the WHO [4] Group 3: Strategic Partnerships and Funding - Valneva's strategic intent to regain rights to the chikungunya vaccine aligns with its commitment to support access in low-and-middle-income countries, as outlined in a funding agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) [2] - CEPI aims to accelerate vaccine development and ensure equitable access, having supported over 70 vaccine candidates against high-risk pathogens [8] Group 4: Serum Institute of India Overview - Serum Institute of India is a global leader in vaccine manufacturing, with an annual capacity of 4 billion doses and a presence in over 170 countries [10][11] - The company focuses on producing affordable vaccines and has played a significant role in reducing the prices of essential vaccines, including those for Diphtheria, Tetanus, and COVID-19 [11]

Group 1 - Casino Group has announced the disposal of its BAO Cash & Carry business in Cameroon to 2S Retail, effective December 31, 2025 [2] - The transaction includes 7 sales outlets, with 5 integrated stores located in Douala and 2 franchised stores in Nkongsamba and Limbe [2] - This divestment aligns with Casino Group's strategy to partner with local entities for international brand development through franchising [2] Group 2 - BAO Cash & Carry, launched in 2018, has become a leading player in the wholesale business in Cameroon, serving over 3,000 active professional customers [3] - 2S Retail plans to maintain the low-cost business model that contributed to BAO Cash & Carry's success and is committed to preserving all existing jobs [4] - The new owner intends to consolidate the current business model in 2026, with plans for a new phase of development starting in 2027 [4]

Core Viewpoint - Zealand Pharma A/S has reported the total number of shares and voting rights as of December 31, 2025, following a share capital increase due to the exercise of employee warrants [1][2]. Group 1: Share Capital and Voting Rights - As of December 31, 2025, Zealand Pharma has a total of 71,515,045 shares, with a nominal value of DKK 1 each, resulting in a share capital of DKK 71,515,045 and an equal number of voting rights [3]. Group 2: Company Overview - Zealand Pharma A/S is a biotechnology company focused on developing medicines for obesity and metabolic health, leveraging over 25 years of peptide R&D expertise and advanced data-driven approaches [4]. - The company has more than ten drug candidates that have entered clinical development, with two products already on the market and three candidates in late-stage development [4]. - Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in Boston, Massachusetts [4].

Schindellegi, Switzerland – 31 December 2025 Trifork Group AGCompany announcement no. 62/2025European Regulatory News Reporting of transactions made by persons discharging managerial responsibilities Pursuant to the Market Abuse Regulation Article 19, Trifork Group AG (Swiss company registration number CHE-474.101.854) (“Trifork”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in Trifork or persons closely associated with them. 1. ...

TAMPA, Fla., Dec. 31, 2025 (GLOBE NEWSWIRE) -- FLUENT Corp. (CSE: FNT.U) (OTCQB: CNTMF) (“FLUENT” or the “Company”), today announced that it has completed the sale of its Pennsylvania operations to HIVE Holdings, Inc., effective December 31, 2025 for US$12.5 million in cash. The proceeds from the transaction were used to reduce FLUENT’s outstanding debt, which is expected to meaningfully enhance its balance sheet, allowing the Company to further concentrate capital and operational resources on its core grow ...

Combined organization secures four new operator wins within three months, signaling strong market momentum Expanded portfolio strengthens support for 70+ operators across 40+ countries with more than 1,000 specialists worldwide HELSINKI, Finland and TORONTO, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Qvantel Oy (“Qvantel” or the “Purchaser”), a global leader in digital BSS and monetization and telecom solutions, today announced the successful completion of its acquisition of Optiva Inc. (“Optiva”) (TSX:OPT), pursuan ...

Not for distribution to U.S. newswire services or dissemination in the United States TORONTO, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Galantas Gold Corporation (TSX-V & AIM: GAL; OTCQB: GALKF) (“Galantas” or the “Company”) is pleased to announce that the Company has completed its previously announced acquisition (the “Transaction”) of all of the issued and outstanding shares of RDL Mining Corp. (“RDL”) in exchange for common shares of Galantas (“Galantas Shares”), pursuant to a share purchase agreement among Gala ...